These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31562960)

  • 21. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT.
    Swoboda R; Labopin M; Giebel S; Schroeder T; Kröger N; Arat M; Savani B; Spyridonidis A; Hamladji RM; Potter V; Berceanu A; Yakoub-Agha I; Rambaldi A; Ozdogu H; Sanz J; Nagler A; Mohty M
    Bone Marrow Transplant; 2023 Mar; 58(3):282-287. PubMed ID: 36460819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
    J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
    Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
    Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission.
    Alfaro Moya T; Mattsson J; Remberger M; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Gerbitz A; Pasic I; Novitzky-Basso I; Michelis FV
    Eur J Haematol; 2023 Oct; 111(4):553-561. PubMed ID: 37461810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression.
    Park S; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2018-2026. PubMed ID: 32659434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
    Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
    Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.
    Sibai H; Falcone U; Deotare U; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Lipton JH; Seftel MD; Messner HA; Kim DDH
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2270-2275. PubMed ID: 27596129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total Marrow Irradiation for Second Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia.
    Dominietto A; Vagge S; di Grazia C; Bregante S; Raiola AM; Varaldo R; Gualandi F; Gusinu M; Barra S; Agostinelli S; Angelucci E; Hui S
    Transplant Cell Ther; 2023 Aug; 29(8):506.e1-506.e6. PubMed ID: 37094701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
    Khalil MMI; Messner HA; Lipton JH; Kim DD; Viswabandya A; Thyagu S; Deotare U; Michelis FV
    Ann Hematol; 2018 Oct; 97(10):1975-1985. PubMed ID: 29947975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
    Yamashita T; Takami A; Uchida N; Fukuda T; Eto T; Shiratori S; Ota S; Akasaka T; Miyakoshi S; Kondo T; Hidaka M; Kanda J; Atsuta Y; Yano S
    Bone Marrow Transplant; 2020 Oct; 55(10):1955-1965. PubMed ID: 32203256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Hamladji RM; Beelen D; Mufti G; Socié G; Delage J; Blaise D; Chevallier P; Forcade E; Deconinck E; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):751-757. PubMed ID: 29247780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Sobczyk-Kruszelnicka M; Stelljes M; Byrne JL; Fegueux N; Beelen DW; Rovira M; Spyridonidis A; Blaise D; Bornhäuser M; Karadogan I; Savani BN; Nagler A; Mohty M;
    Bone Marrow Transplant; 2021 Feb; 56(2):481-491. PubMed ID: 32892216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan.
    Sakaguchi H; Muramatsu H; Hasegawa D; Kudo K; Ishida H; Yoshida N; Koh K; Noguchi M; Shiba N; Tokimasa S; Fukuda T; Goto H; Miyamura T; Nakazawa Y; Hashii Y; Inoue M; Atsuta Y;
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27459. PubMed ID: 30270523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.